August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Wolfgang Miesbach: How Haemophilia Care Has Evolved in China

Wolfgang Miesbach/LinkedIn

May 27, 2026, 15:38

Wolfgang Miesbach: How Haemophilia Care Has Evolved in China

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Yun Wang et al, published in RPTH Journal, adding։

”Same disease – different realities.

Just read a very insightful review by Xue, Poon, Yang and colleagues on how haemophilia care has evolved in China, and it really challenges the usual Euro‑/US‑centric perspective:

The authors describe how China has compressed decades of progress into a short time frame: building a nationwide tiered center network, scaling up domestic plasma‑derived and recombinant factors, introducing new non‑factor therapies, and pushing ahead with multiple AAV gene therapy programs – all while still grappling with underdiagnosis, marked urban–rural disparities, and substantial out‑of‑pocket burden for many patients.

What I find especially interesting is that China is not just copying Western models; strong national policy, local manufacturing, and home‑grown innovation (from rFVIIa and FX activators to anti‑TFPI and anti–protein C antibodies) are turning it into a rapidly emerging source of real‑world data, new drugs, and alternative care structures that could influence haemophilia management well beyond China.”

Title: The therapeutic landscape of inherited bleeding disorders in China

Authors: Yun Wang, Feng Xue, Man-Chiu Poon, Renchi Yang

Wolfgang Miesbach: How Haemophilia Care Has Evolved in China